Testing CS231295 in Advanced Solid Tumors
Part of Cancer clinical trials.
This is an early-stage trial testing a new drug called CS231295 in people with advanced cancers (like lung, pancreatic, or brain tumors) that have stopped responding to standard treatments. The study aims to find the right dose and learn how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced, recurrent, or metastatic solid tumor (cancer that has spread) that failed or you couldn't tolerate standard treatment
- You have at least one measurable tumor visible on imaging scans
- You are 18 years or older with a good overall health status (ECOG score 0–1, or KPS score ≥60 for brain tumors)
- Your blood counts, liver, kidney, and heart function meet specific safety thresholds (tested by blood work and ECG)
- You have not received recent chemotherapy, radiation, or other cancer drugs (usually within 2–4 weeks)
- You are willing to use effective contraception if you can become pregnant or father a child, for the entire study and 12 weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.